logo
banner banner

news details

Home > News >

Company news about Capacity Expansion Project Progress Update for Pharmaceutical Intermediates

Events
Contact Us
Ms. Wang
86-519-85525329
wechat
+86 13585347860
Contact Now

Capacity Expansion Project Progress Update for Pharmaceutical Intermediates

2026-07-17

Xuanming continues to steadily advance its pharmaceutical intermediates capacity expansion project, aiming to strengthen large-scale production capability and improve supply stability for global fine chemical and biopharma customers.

To meet the rapidly growing global demand for high-purity intermediates and custom synthesis orders, we have upgraded core production workshops, reaction systems and supporting purification facilities. The expanded production lines support standardized batch manufacturing, covering laboratory small-batch trials, pilot scale and commercial mass production.

After the capacity upgrade, the factory achieves higher production efficiency, stricter impurity control and more stable batch consistency. It effectively shortens overall lead time and improves delivery reliability for long-term bulk orders.

This expansion also empowers our CDMO custom synthesis business. We can undertake more complex molecular customization projects and support customers’ whole-process drug research and industrialization.

Xuanming will keep optimizing production scale, quality control and supply chain management to provide reliable high-end fine chemical and pharmaceutical intermediate solutions for worldwide partners.

banner
news details
Home > News >

Company news about-Capacity Expansion Project Progress Update for Pharmaceutical Intermediates

Capacity Expansion Project Progress Update for Pharmaceutical Intermediates

2026-07-17

Xuanming continues to steadily advance its pharmaceutical intermediates capacity expansion project, aiming to strengthen large-scale production capability and improve supply stability for global fine chemical and biopharma customers.

To meet the rapidly growing global demand for high-purity intermediates and custom synthesis orders, we have upgraded core production workshops, reaction systems and supporting purification facilities. The expanded production lines support standardized batch manufacturing, covering laboratory small-batch trials, pilot scale and commercial mass production.

After the capacity upgrade, the factory achieves higher production efficiency, stricter impurity control and more stable batch consistency. It effectively shortens overall lead time and improves delivery reliability for long-term bulk orders.

This expansion also empowers our CDMO custom synthesis business. We can undertake more complex molecular customization projects and support customers’ whole-process drug research and industrialization.

Xuanming will keep optimizing production scale, quality control and supply chain management to provide reliable high-end fine chemical and pharmaceutical intermediate solutions for worldwide partners.